La pré-série A de 31 millions de dollars d'Epitopea est un coup de pouce pour les essais cliniques d'immunothérapies à l’ARN
Cet article continue en anglais...
Epitopea’s transatlantic business model has been boosted by a $31million pre-Series A financing round which supports the cancer immunotherapeutics company’s 2026 clinical trials goal.
Based in Montreal, Canada, and on Station Road, Cambridge, Epitopea’s proprietary CryptoMap platform is helping to develop accessible off-the-shelf RNA-based immunotherapies for use in hard-to-treat cancers by targeting a new class of untapped tumour-specific antigens.
These aberrantly-expressed antigens, known as Cryptigen TSAs, are hidden within cancer’s ‘junk’ DNA and are broadly shared across multiple patients with the same tumour type.
The pre-Series A financing brings the total capital raised by Epitopea to more than $45million. New investors Investissement Québec, adMare BioInnovations and Jonathan Milner join existing investors Advent Life Sciences, CTI Life Sciences, Cambridge Innovation Capital, Fonds de Solidarité FTQ, the Harrington Discovery Institute, IRICoR and Novateur Ventures, all of whom also participated in this financing round.
To read the full article click here.
